Suppr超能文献

同时使用烟草和大麻的使用者(共使用者)中的尼古丁和毒物暴露。

Nicotine and Toxicant Exposure Among Concurrent Users (Co-Users) of Tobacco and Cannabis.

机构信息

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY.

出版信息

Nicotine Tob Res. 2020 Jul 16;22(8):1354-1363. doi: 10.1093/ntr/ntz122.

Abstract

BACKGROUND

Smoking cannabis may potentially increase exposure to numerous toxic chemicals that are commonly associated with tobacco use. There is a paucity of data related to toxicant exposures among concurrent users of tobacco and cannabis (co-users).

METHODS

Data are from the Population Assessment of Tobacco and Health Study Wave 1 Biomarker Restricted-Use Files. Analyses focused on adults who provided urine samples (N = 5859). Urine samples were analyzed for biomarkers of exposure to nicotine, tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, and volatile organic compounds. Using weighted linear regression, we compared adjusted geometric mean concentrations of 15 biomarkers between user groups of various tobacco product types according to their self-reported past 30-day cannabis use.

RESULTS

Past 30-day cannabis use was similar across various types of tobacco product use subgroups (range: 13%-23%) and significantly more common compared to non-tobacco users (1.0%; p < .001). Across all groups of tobacco users, those who co-used cannabis exhibited significantly higher concentrations of the biomarker of exposure to acrylonitrile (CYMA) compared to non-cannabis users (by 39%-464%). Tobacco-cannabis co-users also showed significantly elevated levels of the biomarker of exposure to acrylamide (AAMA) compared to exclusive tobacco users, and significantly higher exposure to many polycyclic aromatic hydrocarbons (including fluorene and pyrene).

CONCLUSIONS

Co-users exhibited higher concentrations for biomarkers of exposure to many combustion byproducts, compared to exclusive tobacco users. More robust measurements of cannabis use can address potential confounding in assessments of exposures to tobacco-related constituents, and potential health effects resulting from co-use.

IMPLICATIONS

With disproportionately greater rates of cannabis use occurring among tobacco users, it is critical to consider how concurrent cannabis use may influence health-related outcomes among smokers. Our findings suggest potential additive toxicant exposures among co-users of tobacco and cannabis. Lack of consideration and measurement of cannabis use in assessing tobacco-related exposures may confound estimates thought to be attributable to tobacco, particularly for non-specific biomarkers. Assessing tobacco and cannabis use in tandem will allow for more precise measurement of outcomes related to one or both substances, and can provide additional information on potential health effects related to co-use.

摘要

背景

吸食大麻可能会使人体接触到更多与烟草使用相关的有毒化学物质。目前,关于同时使用烟草和大麻(共使用者)的有毒物质暴露的数据还很有限。

方法

数据来自于人口评估烟草与健康研究第一波生物标志物限制使用文件。分析集中在提供尿液样本的成年人身上(N=5859)。尿液样本用于分析尼古丁、烟草特异性亚硝胺、多环芳烃和挥发性有机化合物的暴露生物标志物。使用加权线性回归,我们根据自我报告的过去 30 天内大麻使用情况,比较了不同烟草制品类型使用者组中 15 种生物标志物的调整后几何平均浓度。

结果

过去 30 天的大麻使用在各种烟草产品使用亚组中相似(范围:13%-23%),与非烟草使用者相比,大麻使用更为常见(1.0%;p<.001)。在所有烟草使用者群体中,与非大麻使用者相比,共使用者尿液中的丙烯腈(CYMA)暴露生物标志物浓度显著更高(高 39%-464%)。烟草-大麻共使用者尿液中的丙烯酰胺(AAMA)暴露生物标志物水平也明显高于单纯烟草使用者,且对许多多环芳烃(包括芴和蒽)的暴露水平也明显升高。

结论

与单纯烟草使用者相比,共使用者尿液中的许多燃烧副产物暴露生物标志物浓度更高。更准确地测量大麻使用情况可以解决在评估与烟草相关成分的暴露时潜在的混杂因素,以及共使用者可能产生的健康影响。

意义

在烟草使用者中,大麻使用的比例不成比例地更高,因此必须考虑同时使用大麻可能如何影响吸烟者的健康相关结果。我们的研究结果表明,烟草和大麻共使用者可能存在潜在的有毒物质暴露。在评估与烟草相关的暴露时,不考虑和测量大麻的使用情况可能会混淆被认为是烟草造成的估计值,特别是对于非特异性生物标志物。同时评估烟草和大麻的使用情况,可以更准确地测量与一种或两种物质相关的结果,并提供与共使用相关的潜在健康影响的额外信息。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验